These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1128 related articles for article (PubMed ID: 15520202)

  • 1. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
    Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
    Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
    Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G
    Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
    Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
    Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
    Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
    Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
    Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
    Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
    Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
    Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
    Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
    Ashley DM; Kong FM; Bigner DD; Hale LP
    Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
    Matsuyama S; Iwadate M; Kondo M; Saitoh M; Hanyu A; Shimizu K; Aburatani H; Mishima HK; Imamura T; Miyazono K; Miyazawa K
    Cancer Res; 2003 Nov; 63(22):7791-8. PubMed ID: 14633705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
    Yoo YA; Kang MH; Kim JS; Oh SC
    Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
    DaCosta Byfield S; Major C; Laping NJ; Roberts AB
    Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone inhibits TGF-beta expression in malignant glioma cells.
    Burghardt I; Tritschler F; Opitz CA; Frank B; Weller M; Wick W
    Biochem Biophys Res Commun; 2007 Mar; 354(2):542-7. PubMed ID: 17234158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta2 regulates growth and differentiation of pulp cells via ALK5/Smad2/3.
    Tai TF; Chan CP; Lin CC; Chen LI; Jeng JH; Chang MC
    J Endod; 2008 Apr; 34(4):427-32. PubMed ID: 18358889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
    Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.